Evo Retrograde
Payments companies reported to CMS as associated with Evo Retrograde. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Evo Retrograde, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Evo Retrograde
These are the largest totals companies reported as associated with Evo Retrograde. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Christopher Lee | Los Angeles, CA | Orthopaedic Trauma | $8,709.88 |
| Anjan Shah | Brandon, FL | Orthopaedic Surgery | $8,417.52 |
| Thomas Shuler | Roanoke, VA | Orthopaedic Surgery | $8,360.84 |
| Eric Fulkerson | Walnut Creek, CA | Orthopaedic Trauma | $8,012.82 |
| Christopher Hoshino | Torrance, CA | Orthopaedic Trauma | $7,879.62 |
| Matthew Garner | Enola, PA | Orthopaedic Surgery | $7,879.62 |
| Adam Taylor | Sacramento, CA | Adult Reconstructive Orthopaedic Surgery | $515.00 |
| Daniel Choi | Torrance, CA | Orthopaedic Surgery | $449.70 |
| Ryan Deangelis | Lexington, KY | Orthopaedic Trauma | $381.95 |
| Alexander Upfill-Brown | Los Angeles, CA | Orthopaedic Surgery | $361.92 |
Prescribed Evo Retrograde?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.